Kymera Therapeutics, Inc. (KYMR)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$136.25+7.21%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · KYMR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance dropped from the top half to the bottom half of its industry over the past month — the reason to own it has weakened.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 35.6% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| -54.7% |
Growth built into the price is above our model estimate.
The price assumes 90.3 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 65 industry peers · Company calendar date is not available
KYMR — earnings miss
Dated 2026-10-29
Results of Operations and Financial Condition On October 29, 2026, Kymera Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K. The information in this Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise sub…
Why it matters: The Phase 2b trial tests KT-621 in moderate to severe eosinophilic asthma. Its main lung-function result will show whether the drug helps patients.
Watch forKymera reports results in late 2027. The main FEV1 measure improves over placebo, with no new safety concern.
Also watch forThe main FEV1 measure shows no improvement over placebo. A safety concern emerges, or results come after late 2027.
Why it matters: The Phase 2b results test whether KT-621 helps people with moderate to severe atopic dermatitis. The data guide the planned Phase 3 start.
Watch forKymera reports Week 16 results by year-end 2026. The main EASI measure shows a clear benefit, with no new safety concern.
Also watch forThe main EASI measure shows no benefit over placebo. Safety concerns emerge, or results come after year-end 2026.
Why it matters: Kymera reported $1.6 billion in cash and investments and plans heavy research spending. A shorter runway could limit work across its trials.
Worry ifKymera reports less than $1.5 billion in cash and investments, or moves its stated runway to before 2029.
Less concerning ifKymera keeps its stated runway into 2029 and reports cash and investments at or above $1.5 billion.
Why it matters: Gilead is leading KT-200 toward an IND filing. A filing would move the partnered cancer drug closer to human testing.
Supportive ifGilead files an IND for KT-200 in 2027, as stated in the company update.
Worry ifGilead does not file the IND in 2027, or reports that the program is delayed or stopped.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$151 on $10,000 · ±1.5% | How much price usually moves either way. |
| Bad day | $429 loss on $10,000 · 4.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,774 loss on $10,000 · 27.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The healthy-volunteer trial showed strong IRF5 loss and lower immune markers. LUMORA will test whether this effect appears in people with lupus.
Watch forKymera starts LUMORA by early 2027. The 16-week study shows changes in lupus biomarkers, with no major safety issue.
Also watch forLUMORA does not start by early 2027, or the study shows no change in key biomarkers or a serious safety concern.